Trial Profile
Randomized, controlled Phase 1/2 study to evaluate the safety and effectiveness of an enhanced potency adjuvanted seasonal influenza vaccine in patients with chronic disease and the elderly
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Adjuvanted-influenza-virus-vaccine-inactivated-trivalent-Vaxine (Primary) ; ADVAX (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Vaxine
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 01 Sep 2011 New trial record